

Correction to Letter to the Editor "Prevalence and causes of rifampicin-resistance genotypic/phenotypic discrepancy detected on Xpert MTB/RIF in Singapore" [Ann Acad Med Singap 2024;12:766]

The authors would like to make a correction in the publication of the [original article](#).

The previous line "WHO has reported 24 disputed *rpoB* mutations, which account for 12% of RIF resistance based on surveillance data."⁹ has been updated to "WHO has reported 7 disputed *rpoB* mutations, which account for 12% of RIF resistance based on surveillance data."⁹

REFERENCE

9. World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Published 5 February 2021. <https://www.who.int/publications/i/item/9789240017283>. Accessed 14 October 2024. Pages xiv, 39.

The authors would like to apologise for any inconvenience caused.